Lessons from Covid-19 | ‘Big Science’ with Large-Scale Research and Development Projects, and Read and Write on the Code of Life | Jian Wang and Xun Xu | Distinguished Speaker Series | Duke Kunshan University

Lessons from Covid-19 | ‘Big Science’ with Large-Scale Research and Development Projects, and Read and Write on the Code of Life | Jian Wang and Xun Xu | Distinguished Speaker Series

E.g., 06/16/2022
E.g., 06/16/2022
10:15 to 11:30
AB 2103

‘Big Science’ with Large-Scale Research and Development Projects & Read and Write on the Code of Life

Do you want to meet with the heroes of Covid-19 who went to Wuhan on the second day of lockdown and established Fire Eye detection labs within five days? Are you interested in learning more about the latest trend in life sciences research and development?

Join our Distinguished Speaker Series lecture by BGI Group Chairman Jian Wang and CEO Xun Xu, and ask them any questions you have on Covid-19, life sciences, etc.

Jian Wang, co-founder and chairman of BGI Group, was born in Yuanling, Hunan province, in 1954. He graduated from Hunan Medical College in 1979 and obtained a master’s degree in integrated medicines from Beijing University of Chinese Medicine in 1986. From 1988 to 1994, he continued his studies overseas focusing on cell proliferation and differentiation as a research fellow at the University of Texas, the University of Iowa and the University of Washington.

Inspired by the international Human Genome Project (HGP) in 1991, Wang established the Seattle Chinese Biomedical Association and planned to introduce the project back to China. He returned to China in 1994 and set up Jubilee Biotechnology (Beijing) Co. Ltd. in an effort to promote HGP. In 1999, he co-founded BGI to engage in research contributing to HGP. From 2003 to 2007, he served as deputy director of the Institute of Genomics at the Chinese Academy of Sciences. In 2007, BGI moved from Beijing to Shenzhen, focusing on the organizational task of integrating research, education and industry.

Over the past two decades, Wang has remained true to his aspiration and belief that advancing omics and related technologies will benefit people everywhere. To achieve this goal, BGI has formed a unique development model – scientific discovery, technological invention and industrial development, in coordination with cultivating talent and developing new fields of study and industrial applications. He has served as the decision-maker and leader for research and application projects at BGI, leading a group of experts to make a number of remarkable achievements, including the International HapMap Project (undertaking 10 percent of the workload), Chinese Genome Map and International 1000 Genomes Project. BGI has created a world-class foundation in life sciences and omics technology, as well as an applied research system, operating the China National GeneBank and manufacturing fully automated nucleic acids sequencers, a capability only achieved by less than a handful of companies worldwide. Recently, Wang led a successful initial public offering of BGI Genomics in the Chinese stock exchange, and it is the best-performed stock in China this year. He has established a complete system of trans-omics reading, writing and storage. He is determined to make collaborative efforts to control the birth defects, cancer, and infectious diseases.

Wang is devoted to health and fitness, both practicing an active lifestyle, and helping to inspire others. He takes the pursuit of human’s ultimate goal and meaning as his own responsibility, aiming to challenge the limits of life sciences, improve the community of shared future for mankind in the new era. He believes in that it must start with self-practice before benefitting all mankind.

He is a fan of extreme sports including snowboarding, windsurfing and climbing. He has conquered some of the world’s highest peaks, including Mountain Everest at the age of 56.

XU Xun is CEO of BGI Group, and president and chief scientist of BGI Research. His research focuses on the genetic sequencing technologies, single-cell sequencing, DNA synthesizer, and the applications of sequencing technologies in disease management and agriculture.

He has authored or co-authored 223 scientific papers published in top peer-reviewed journals listed in SCI including Nature, Science, and Cell. Xu has led 15 major national scientific research projects and several international projects, including China National 863 Sequencing Instrument Development Project and Million Microbiome of Humans Project.